Impact of Bevel Orientation on Arteriovenous Fistula Puncture in Hemodialysis

NCT ID: NCT06708338

Last Updated: 2025-07-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

240 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-01

Study Completion Date

2029-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

End-stage renal disease (ESRD) is a condition in which the filtration function of the kidneys has deteriorated, necessitating dialysis or transplantation. With an aging population, the number of patients undergoing dialysis for CKD is constantly increasing.

There are different types of dialysis treatment: hemodialysis and peritoneal dialysis.

Hemodialysis involves exchanges between blood and a dialysate (a liquid used to purify blood) via a dialyzer (artificial filter), coordinated by a generator. This method requires a vascular approach, of which there are 3 types: the arteriovenous fistula (AVF), the arteriovenous graft and the central venous catheter.

The AVF remains the vascular access of choice for hemodialysis sessions, and its preservation is an essential objective for patients with CKD.

One of the major challenges for AVFs is to achieve a successful puncture, an act performed around 310 times a year per patient, for dialysis performed three times a week with double needles. This repeated procedure can cause damage to the AVF, leading to complications such as stenosis, thrombosis, aneurysm, superficial infection, hematoma, bleeding, parietal rupture or dissection.

However, there is no official recommendation on the most conservative puncture technique for AVF. In view of the number of patients concerned and the recurrence of puncture, it would seem essential to evaluate the impact of bevel orientation on the occurrence of complications during dialysis by means of a randomized prospective study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

End-Stage Renal Disease Requiring Haemodialysis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bevel-up group

AVF puncture will be performed with the needle bevel facing up for the entire duration of the patient's participation.

Group Type ACTIVE_COMPARATOR

Needle bevel orientation for arteriovenous fistula puncture

Intervention Type PROCEDURE

For the duration of the study (24 months from inclusion), the nurse will puncture the AVF according to the patient's randomization arm.

Patients will be randomized, according to the minimization technique, in a 1:1 ratio between the following two groups:

* Bevel-up group
* Bevel-down group

Bevel-down group

AVF puncture will be performed with the needle bevel facing down for the entire duration of the patient's participation

Group Type EXPERIMENTAL

Needle bevel orientation for arteriovenous fistula puncture

Intervention Type PROCEDURE

For the duration of the study (24 months from inclusion), the nurse will puncture the AVF according to the patient's randomization arm.

Patients will be randomized, according to the minimization technique, in a 1:1 ratio between the following two groups:

* Bevel-up group
* Bevel-down group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Needle bevel orientation for arteriovenous fistula puncture

For the duration of the study (24 months from inclusion), the nurse will puncture the AVF according to the patient's randomization arm.

Patients will be randomized, according to the minimization technique, in a 1:1 ratio between the following two groups:

* Bevel-up group
* Bevel-down group

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* male or female with Chronic Kidney Disease
* patient requiring 4-hour hemodialysis sessions, 3 times per week, in a dialysis center
* Native arteriovenous fistula (AVF) (without prosthesis), mature, with no prior puncture, located in the upper limb
* First fistula for a hemodialysis patient
* Expected duration of dialysis ≥ 1 year
* Double-needle dialysis
* Hemodialysis possible on AVF
* Average AVF flow rate between 500 and 2,000 mL/min
* Affiliated with a social security scheme
* Free and informed consent

Exclusion Criteria

* Auto-dialysis at home
* Puncture using the buttonhole technique
* Patient requiring AVF puncture with a catheter
* Planned transplant within the next 12 months
* Previous AVF creation, except for the fistula of interest
* Patient with a history of cancer within the past 5 years or active cancer
* Patient under court protection or guardianship
* Pregnant and breast-feeding women
* Patient with psychiatric pathologies or cognitive disorders
* Patient follow-up difficult or impossible for geographical or other reasons, at the investigator's discretion
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Emile Roux

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Hospitalier Emile Roux

Le Puy-en-Velay, , France

Site Status

Hôpital Saint Joseph Saint Luc

Lyon, , France

Site Status

Centre Hospitalier de Moulins-Yzeure

Moulins, , France

Site Status

Ctre Hospitalier Intercommunal Poissy St Germain Site Poissy

Poissy, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

David SOULIER

Role: CONTACT

0471043875

Camille FARCY

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Claire REYMOND

Role: primary

0471043403

Julie GROS

Role: backup

Sophie MILLET

Role: primary

+33 4 78 61 87 14

Nelly DOMPNIER

Role: primary

+33 4 70 35 79 69

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2024-A01536-41

Identifier Type: OTHER

Identifier Source: secondary_id

RIPH2_SOULIER_FAVORI

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.